Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing targeted medicines for patients with severe autoimmune and inflammatory diseases. The company's business model centers on an internal drug discovery engine that combines immunobiology, medicinal and computational chemistry, protein biochemistry, and artificial intelligence to identify and inhibit key signaling nodes within the innate immune system.
Odyssey's pipeline features both small molecule and protein therapeutics. Its most advanced candidate, OD-001 (also known as OD-07656), is an oral small-molecule scaffolding inhibitor of receptor-interacting protein kinase 2 (RIPK2) currently in Phase 2a clinical trials for the treatment of ulcerative colitis. Another key program, OD-002, is an oral small-molecule inhibitor of SLC15A4 designed to block pathogenic inflammatory responses in conditions like systemic lupus erythematosus. The company is also advancing preclinical assets, including OD-003, a protein therapeutic targeting tumor necrosis factor receptor 2 (TNFR2), and inhibitors targeting IRAK4.
As a pre-revenue, clinical-stage entity, Odyssey Therapeutics does not currently generate commercial product sales. Instead, it relies on capital raised through equity offerings—including its 2026 initial public offering—and strategic collaboration agreements with major pharmaceutical companies to fund its extensive research and development activities. Operating primarily out of its headquarters in Boston, Massachusetts, the company competes in the highly competitive immunology and inflammation space against both established pharmaceutical giants and specialized biotechnology firms.
